BLAINJECTIONINJECTABLE
Approved
May 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
6
Data completeness
3/8 — Basic
Drug data last refreshed 14h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AIMOVIG (erenumab-aooe) is a monoclonal antibody developed by Amgen approved in May 2018 for migraine prevention. It is administered via subcutaneous injection and represents the first in a new class of CGRP-targeting migraine therapeutics. The drug works by binding to calcitonin gene-related peptide (CGRP) receptor to reduce migraine frequency in patients with chronic or episodic migraine.
Peak
AIMOVIG is in peak commercial phase with moderate competitive pressure (30/100), indicating a mature market with established field teams and infrastructure supporting the franchise.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
Started May 2022
5 enrolled
Trigeminal Neuropathy
Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)
Started May 2022
5 enrolled
Temporomandibular Disorders
Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder
Started Nov 2021
30 enrolled
Temporomandibular Disorder
Aimovig Pregnancy Exposure Registry
Started Jan 2021
2,842 enrolled
Migraine
Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data
Started Aug 2020
1,839 enrolled
Migraine
Worked on AIMOVIG at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.